[go: up one dir, main page]

HUP0100670A2 - Vírusokat tartalmazó készítmények és eljárások víruspreparátumok töményítésére - Google Patents

Vírusokat tartalmazó készítmények és eljárások víruspreparátumok töményítésére

Info

Publication number
HUP0100670A2
HUP0100670A2 HU0100670A HUP0100670A HUP0100670A2 HU P0100670 A2 HUP0100670 A2 HU P0100670A2 HU 0100670 A HU0100670 A HU 0100670A HU P0100670 A HUP0100670 A HU P0100670A HU P0100670 A2 HUP0100670 A2 HU P0100670A2
Authority
HU
Hungary
Prior art keywords
virus
preparations
concentration
compositions
viruses
Prior art date
Application number
HU0100670A
Other languages
English (en)
Inventor
Laureano L. Bondoc
Andreas Frei
Peter Ihnat
Henry K. H. Kwan
Frederick William Porter Iv
Varda E. Sandweiss
John Chu-Tay Tang
Gary J. Vellekamp
Pui-Ho Yuen
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0100670A2 publication Critical patent/HUP0100670A2/hu
Publication of HUP0100670A3 publication Critical patent/HUP0100670A3/hu
Publication of HU226015B1 publication Critical patent/HU226015B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát új, vírustartalmú készítmények képezik, valamintúj eljárások vírustartalmú, különösen vírusvektorokat tartalmazókészítmények töményítésére és tisztítására. A készítményekpolihidroxi-szénhidrogén-puffert tartalmaznak a pH körülbelül 7 éskörülbelül 8,5 közötti tartományban tartása céljából, körülbelül 2 °Cés 27 °C közötti hőmérséklet-tartományban. A találmány szerintikészítmények szignifikánsan javított stabilitással rendelkeznek éskülönösen hasznosak terápiás alkalmazásokban, például génterápiában.Meglévő víruspreparátumok töményítésére szolgáló eljárásban avíruspreparátum anioncserélő kromatográfiára kerül, majd avíruspreparátum-termékhez hozzáadnak polihidroxi-szénhidrogént, éstangenciális áramlással való szűréssel növelik a víruspreparátum-termékben lévő vírus koncentrációját, és egy további feldolgozásilépésben méretkizáráson alapuló kromatográfiát végeznek. Ó
HU0100670A 1998-02-17 1999-02-12 Compositions and preparations comprising viruses HU226015B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Publications (3)

Publication Number Publication Date
HUP0100670A2 true HUP0100670A2 (hu) 2001-06-28
HUP0100670A3 HUP0100670A3 (en) 2003-10-28
HU226015B1 HU226015B1 (en) 2008-02-28

Family

ID=26698472

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100670A HU226015B1 (en) 1998-02-17 1999-02-12 Compositions and preparations comprising viruses

Country Status (24)

Country Link
EP (4) EP1526174B1 (hu)
JP (3) JP4358434B2 (hu)
KR (5) KR101018992B1 (hu)
CN (2) CN101164623B (hu)
AR (3) AR020054A1 (hu)
AT (3) ATE478945T1 (hu)
AU (1) AU757976B2 (hu)
BR (1) BR9908015A (hu)
CA (2) CA2320419C (hu)
CO (1) CO4820440A1 (hu)
DE (3) DE69936948T2 (hu)
DK (1) DK1054955T3 (hu)
ES (2) ES2290613T3 (hu)
HU (1) HU226015B1 (hu)
ID (1) ID28298A (hu)
IL (2) IL137510A0 (hu)
MY (1) MY141641A (hu)
NO (1) NO20004104L (hu)
PE (1) PE20000265A1 (hu)
PL (1) PL197747B1 (hu)
PT (1) PT1054955E (hu)
SK (1) SK11842000A3 (hu)
TW (1) TWI232107B (hu)
WO (1) WO1999041416A2 (hu)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000029024A1 (en) * 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2002047726A2 (en) * 2000-12-12 2002-06-20 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
EP1465664A1 (en) * 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
EP1780269B1 (en) 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
JP4621743B2 (ja) 2004-12-13 2011-01-26 カンジ，インコーポレイテッド 複製欠損アデノウイルスの産生のための細胞株
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
ATE497010T1 (de) 2005-12-12 2011-02-15 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
DK2536829T3 (en) 2010-02-15 2016-07-04 Crucell Holland Bv A process for the production of Ad26-adenovirus vectors
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA201390810A1 (ru) * 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
DK2702147T3 (da) * 2011-04-29 2020-09-28 Oncolytics Biotech Inc Fremgangsmåder til oprensning af vira ved hjælp af gelpermeationskromatografi
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
KR102023791B1 (ko) 2012-03-22 2019-09-23 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
WO2015183180A1 (en) * 2014-05-28 2015-12-03 Agency For Science, Technology And Research Virus reduction method
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
MX393584B (es) 2016-06-20 2025-03-21 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
JP2020533367A (ja) 2017-09-15 2020-11-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖに対する免疫の安全な誘導方法
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CN114173827B (zh) * 2019-06-28 2025-01-28 武田药品工业株式会社 腺相关病毒纯化方法
EP4097122A4 (en) 2020-01-31 2024-07-17 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
WO2021186246A1 (en) * 2020-03-19 2021-09-23 Trizell Ltd. Temperature-responsive virus storage system
EP4294436A1 (en) 2021-02-19 2023-12-27 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb fantigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN115989321A (zh) * 2021-08-17 2023-04-18 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (hu) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
KR20010072547A (ko) 2001-07-31
ATE478945T1 (de) 2010-09-15
DE69933433T2 (de) 2007-08-23
DE69933433D1 (de) 2006-11-16
CA2320419A1 (en) 1999-08-19
EP1526173A3 (en) 2005-08-10
MY141641A (en) 2010-05-31
PL197747B1 (pl) 2008-04-30
EP1526174A2 (en) 2005-04-27
CN101164623A (zh) 2008-04-23
CN101164623B (zh) 2012-11-14
KR100918187B1 (ko) 2009-09-22
ES2290613T3 (es) 2008-02-16
CN100374551C (zh) 2008-03-12
EP1526174A3 (en) 2005-08-31
AR020054A1 (es) 2002-04-10
TWI232107B (en) 2005-05-11
ES2272053T3 (es) 2007-04-16
IL137510A0 (en) 2001-07-24
KR100912362B1 (ko) 2009-08-19
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
EP1054955A2 (en) 2000-11-29
EP1741777A1 (en) 2007-01-10
EP1526174B1 (en) 2007-08-22
KR20090127947A (ko) 2009-12-14
HK1073481A1 (en) 2005-10-07
ID28298A (id) 2001-05-10
KR20080065614A (ko) 2008-07-14
KR20090038927A (ko) 2009-04-21
DK1054955T3 (da) 2007-01-15
DE69936948T2 (de) 2008-05-15
PE20000265A1 (es) 2000-04-25
CN1297478A (zh) 2001-05-30
KR100991683B1 (ko) 2010-11-04
KR20080065615A (ko) 2008-07-14
AR063314A2 (es) 2009-01-21
IL137510A (en) 2012-10-31
NO20004104D0 (no) 2000-08-16
PT1054955E (pt) 2007-01-31
HUP0100670A3 (en) 2003-10-28
JP2010213727A (ja) 2010-09-30
HK1097413A1 (en) 2007-06-22
EP1741777B1 (en) 2010-08-25
KR100862169B1 (ko) 2008-10-09
EP1054955B1 (en) 2006-10-04
ATE341614T1 (de) 2006-10-15
KR101018992B1 (ko) 2011-03-07
EP1526173A2 (en) 2005-04-27
JP2002503484A (ja) 2002-02-05
DE69936948D1 (de) 2007-10-04
NO20004104L (no) 2000-10-17
PL342847A1 (en) 2001-07-16
WO1999041416A2 (en) 1999-08-19
AU757976B2 (en) 2003-03-13
CA2723040A1 (en) 1999-08-19
BR9908015A (pt) 2001-04-24
WO1999041416A3 (en) 1999-11-18
ATE371020T1 (de) 2007-09-15
HU226015B1 (en) 2008-02-28
CA2320419C (en) 2011-02-08
AR063315A2 (es) 2009-01-21
JP4358434B2 (ja) 2009-11-04
DE69942708D1 (de) 2010-10-07
EP1526173B1 (en) 2012-11-21
CO4820440A1 (es) 1999-07-28
AU2653899A (en) 1999-08-30
SK11842000A3 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
HUP0100670A2 (hu) Vírusokat tartalmazó készítmények és eljárások víruspreparátumok töményítésére
Bishop et al. The low molecular weight RNAs of Rous sarcoma virus: II. The 7 S RNA
Brodsky et al. Caprylic acid precipitation method for impurity reduction: an alternative to conventional chromatography for monoclonal antibody purification
ES2349046T3 (es) Métodos para purificar virus.
Seidel et al. The conformation of myosin during the steady state of ATP hydrolysis: studies with myosin spin labeled at the S1 thiol groups
CN104099310B (zh) 一种重组核酸酶及其制备方法
BR0013277A (pt) Derivados de 3(5) ureido-pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
DK0743949T3 (da) Fremgangsmåde til fremstilling af endotoksinfrie eller endotoksinfattige nukleinsyrer og/eller oligonukleotider til gentera
FR2716682B1 (fr) Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
HUP0102478A2 (hu) A HCV-burokfehérjék által alkotott részecskék alkalmazása vakcinázásban
NO973685L (no) Multi-tumor avvikende vekstgener
JP3438735B2 (ja) 上清ｉｖ、特にｉｖ−４またはコーンフラクションｖまたはそれと類似の上清または画分からヒトアルブミンを単離する方法
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
JPH0112760B2 (hu)
DE3686954D1 (de) Loeslichkeits-, reinigungs- und charakterisierungsverfahren fuer proteine aus unloeslichen proteinaggregaten oder proteinkomplexen und diesbezuegliche praeparate.
Dietzschold et al. Serological characterization of the three major proteins of vesicular stomatitis virus
CA2069460A1 (en) Methods and compositions for preparation and use of a herpes protease
Durban et al. Purification and characterization of a nuclear DNA-binding phosphoprotein in fetal and tumor tissues
Litman et al. Evidence for a conformational change in the 30 S E. coli ribosomal subunit upon formation of 70 S particles
JPH0479359B2 (hu)
Borecký et al. Electrophoretic profiles and activities of human interferon in heterologous cells
Graziadei III et al. Translation of reovirus messenger ribonucleic acids synthesized in vitro into reovirus proteins in a mouse L cell extract
EP3871690A1 (en) Method for virus production
EP0868507B1 (en) Process for the purification of urease from helicobacter pylori
Furukawa et al. Enhanced poliovirus replication in cytomegalovirus-infected human fibroblasts

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees